Prescription‐event and other forms of epidemiological monitoring of side‐effects in the UK
- 1 July 1999
- journal article
- research article
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 29 (S3) , 217-239
- https://doi.org/10.1046/j.1365-2222.1999.0290s3217.x
Abstract
The post‐marketing surveillance (PMS) of drugs is necessary because of the limited size of the clinical safety database at the time of marketing. The principal hypothesis‐generating methods of PMS are spontaneous reporting (e.g. the yellow card) and Prescription Event Monitoring. These methods are discussed in this chapter and certain basic pharmacoepidemiological issues that are relevant are briefly reviewed.Keywords
This publication has 37 references indexed in Scilit:
- Post-Marketing StudiesDrug Safety, 1998
- Extent and Timing of the Last Glacial Maximum in Southwestern AlaskaQuaternary Research, 1994
- Primary non-compliance with prescribed medication in primary care.BMJ, 1993
- Drug safety alerts — a review of ‘current problems’Pharmacoepidemiology and Drug Safety, 1992
- Safety monitoring: Methodology of the past and of the futurePharmacoepidemiology and Drug Safety, 1992
- Validation of information recorded on general practitioner based computerised data resource in the United Kingdom.BMJ, 1991
- Art Works as CommodityCirca, 1987
- Contents, Vol. 35, No. 4, 1981Psychotherapy and Psychosomatics, 1981
- Adverse reactions to drugs.BMJ, 1965
- The design and logic of a monitor of drug useJournal of Chronic Diseases, 1965